Literature DB >> 21669246

Surfactant protein C is an essential constituent for mucosal adjuvanticity of Surfacten, acting as an antigen delivery vehicle and inducing both local and systemic immunity.

Dai Mizuno1, Takashi Kimoto, Tsunetomo Takei, Akiho Fukuta, Wakako Shinahara, Etsuhisa Takahashi, Mihiro Yano, Hiroshi Kido.   

Abstract

We have reported that Surfacten(®) (St), a bovine pulmonary surfactant free of antigenic c-type lectins, is a useful mucosal adjuvant for nasal vaccination. To prepare ample supplies a synthetic adjuvant that mimics St, we analyzed essential constituents of St for mucosal adjuvanticity. Intranasal inoculation of influenza virus hemagglutinin (HA) vaccine combined with St free of surfactant protein (SP)-C resulted in failure of HA vaccine delivery to dendritic cells and loss of local and systemic immune responses. Naïve bovine SP-C, synthetic human or bovine SP-C peptide reconstituted with three major St lipids restored delivery activity and local and systemic immune responses to levels similar to those of St and provided almost complete protection against lethal doses of influenza virus challenge in mice. The delivery of fluoresceinated HA vaccine to cultured dendritic cells was significantly enhanced by co-administration of St or synthetic adjuvant, and moderately stimulated the expression of MHC class II and CD86. In addition, both St and synthetic adjuvant markedly sustained HA vaccine and achieved a wide antigen distribution in murine nasal cavity. These results suggest that synthetic mucosal adjuvant reconstituted with SP-C peptide and major St lipids is useful for ample supply of the potent mucosal adjuvant as an antigen delivery vehicle for intranasal vaccination.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21669246     DOI: 10.1016/j.vaccine.2011.05.090

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  7 in total

1.  Persistence of LPS-induced lung inflammation in surfactant protein-C-deficient mice.

Authors:  Stephan W Glasser; Melissa D Maxfield; Teah L Ruetschilling; Henry T Akinbi; John E Baatz; Joseph A Kitzmiller; Kristen Page; Yan Xu; Erik L Bao; Thomas R Korfhagen
Journal:  Am J Respir Cell Mol Biol       Date:  2013-11       Impact factor: 6.914

2.  Oral clarithromycin enhances airway immunoglobulin A (IgA) immunity through induction of IgA class switching recombination and B-cell-activating factor of the tumor necrosis factor family molecule on mucosal dendritic cells in mice infected with influenza A virus.

Authors:  Etsuhisa Takahashi; Kosuke Kataoka; Irene L Indalao; Keiko Konoha; Kazuyuki Fujii; Junji Chida; Dai Mizuno; Kohtaro Fujihashi; Hiroshi Kido
Journal:  J Virol       Date:  2012-08-15       Impact factor: 5.103

3.  Endocine™, N3OA and N3OASq; three mucosal adjuvants that enhance the immune response to nasal influenza vaccination.

Authors:  Tina Falkeborn; Andreas Bråve; Marie Larsson; Britt Akerlind; Ulf Schröder; Jorma Hinkula
Journal:  PLoS One       Date:  2013-08-08       Impact factor: 3.240

4.  Genetic replacement of surfactant protein-C reduces respiratory syncytial virus induced lung injury.

Authors:  Stephan W Glasser; Albert P Senft; Melissa D Maxfield; Teah L Ruetschilling; John E Baatz; Kristen Page; Thomas R Korfhagen
Journal:  Respir Res       Date:  2013-02-12

5.  Intranasal influenza vaccination using a new synthetic mucosal adjuvant SF-10: induction of potent local and systemic immunity with balanced Th1 and Th2 responses.

Authors:  Takashi Kimoto; Dai Mizuno; Tsunetomo Takei; Takuya Kunimi; Shinji Ono; Satoko Sakai; Hiroshi Kido
Journal:  Influenza Other Respir Viruses       Date:  2013-05-26       Impact factor: 4.380

6.  Adjuvanting influenza hemagglutinin vaccine with a human pulmonary surfactant-mimicking synthetic compound SF-10 induces local and systemic cell-mediated immunity in mice.

Authors:  Hyejin Kim; Takashi Kimoto; Satoko Sakai; Etsuhisa Takahashi; Hiroshi Kido
Journal:  PLoS One       Date:  2018-01-25       Impact factor: 3.240

Review 7.  Innovative Mucosal Vaccine Formulations Against Influenza A Virus Infections.

Authors:  Cynthia Calzas; Christophe Chevalier
Journal:  Front Immunol       Date:  2019-07-17       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.